Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases

International Journal of Urology

Volumn 17, Issue 11, 2010, Pages 914-922

  Moreira, Daniel M ^a,c   Presti Jr, Joseph C ^d   Aronson, William J ^e,f   Terris, Martha K ^h   Kane, Christopher J ^g   Amling, Christopher L ⁱ   Sun, Leon L ^a   Moul, Judd W ^a   Freedland, Stephen J ^a,b,c  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UCLA MEDICAL CENTER   (United States)

^g UCSD MEDICAL CENTER   (United States)

^h MEDICAL COLLEGE OF GEORGIA   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Disease free survival; Nomograms; Prostate cancer; Prostate specific antigen; Prostatectomy; Validation studies

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; AGED; ARTICLE; BODY MASS; CANCER RECURRENCE; CANCER STAGING; DATA BASE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RACE; RETROSPECTIVE STUDY;

EID: 77958516901     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02631.x     Document Type: Article

References (30)

1. Klein EA, Bianco FJ, Serio AM et al. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J. Urol. 2008; 179: 2212-16, discussion 2216-17.
2. Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-9.
3. Thompson IM Jr, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296: 2329-35.
4. Wiegel T, Bottke D, Steiner U et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J. Clin. Oncol. 2009; 20: 2898-9.
5. Bolla M, Van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-8.
6. Trock BJ, Han M, Freedland SJ et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 2760-9.
7. Chun FK, Karakiewicz PI, Briganti A. Prostate cancer diagnosis: importance of individualized risk stratification models over PSA alone. Eur. Urol. 2008; 54: 241-2.
8. Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW. An updated catalog of prostate cancer predictive tools. Cancer 2008; 113: 3075-99.
9. Moreira DM, Presti JC Jr, Aronson WJ et al. Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2010; 105: 1541-7.
10. Moreira DM, Presti JC Jr, Aronson WJ et al. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J. Urol. 2009; 182: 2250-5.
11. Fitzsimons NJ, Sun LL, Dahm P et al. A single-institution comparison between radical perineal and radical retropubic prostatectomy on perioperative and pathological outcomes for obese men: an analysis of the Duke Prostate Center database. Urology 2007; 70: 1146-51.
12. Schroeck FR, Sun L, Freedland SJ, Jayachandran J, Robertson CN, Moul JW. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2008; 11: 371-6.
13. Cookson MS, Aus G, Burnett AL et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J. Urol. 2007; 177: 540-5.
14. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74.
15. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl. Cancer Inst. 1998; 90: 766-71.
16. Stephenson AJ, Scardino PT, Eastham JA et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Clin. Oncol. 2005; 23: 7005-12.
17. Cooperberg MR, Pasta DJ, Elkin EP et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J. Urol. 2005; 173: 1938-42.
18. Moul JW, Connelly RR, Lubeck DP et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J. Urol. 2001; 166: 1322-7.
19. Roberts WW, Bergstralh EJ, Blute ML et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001; 57: 1033-7.
20. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982; 247: 2543-6.
21. Svatek RS, Jeldres C, Karakiewicz PI et al. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate 2009; 69: 886-94.
22. Shariat SF, Walz J, Roehrborn CG et al. Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy. J. Urol. 2008; 179: 1593-7.
23. Kattan MW, Shariat SF, Andrews B et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J. Clin. Oncol. 2003; 21: 3573-9.
24. Eggener SE, Vickers AJ, Serio AM et al. Comparison of models to predict clinical failure after radical prostatectomy. Cancer 2009; 115: 303-10.
25. Isharwal S, Miller MC, Epstein JI et al. Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy. Int. J. Cancer 2008; 123: 2636-43.
26. Bjartell AS, Al-Ahmadie H, Serio AM et al. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin. Cancer Res. 2007; 13: 4130-8.
27. Kinoshita H, Kamoto T, Nishiyama H, Nakamura E, Matsuda T, Ogawa O. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males. Int. J. Urol. 2007; 14: 930-4 discussion 934.
28. Shen S, Lepor H, Yaffee R, Taneja SS. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J. Urol. 2005; 173: 777-80.
29. Stephenson AJ, Kattan MW, Eastham JA et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J. Clin. Oncol. 2006; 24: 3973-8.
30. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J. Urol. 2006; 176: 1404-8.